ALK+

Questions discussed in this category

How would you treat a patient with metastatic NSCLC >50% PDL-1 positive AND an EGFR or ALK gene mutation/rearrangement in the first-line setting?

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...

2 Answers available

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2015-10-22

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

The New England journal of medicine, 2016-11-10

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

J Thorac Oncol,

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

Clin. Cancer Res., 2015 May 27

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Lancet (London, England), 2017-01-21

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Lancet (London, England), 2016-04-09

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

The New England journal of medicine, 2018-06-14

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

The Lancet. Respiratory medicine, 2019-05

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Ann. Oncol.,

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

The New England journal of medicine, 2018-12-13

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Related Topics